Literature DB >> 2704824

Effect of intravenous fructose on the P-31 MR spectrum of the liver: dose response in healthy volunteers.

F Terrier1, P Vock, J Cotting, R Ladebeck, J Reichen, D Hentschel.   

Abstract

Dynamic phosphorus-31 magnetic resonance (MR) spectroscopy of the liver after intravenous administration of fructose has been suggested as a test of liver function. To establish dose-response curves of the phosphorus metabolites in the normal human liver, each of four healthy volunteers was given two to four different fructose doses on separate days: 62.5, 125, 250, 375, or 500 mg per kilogram of body weight. P-31 MR spectra of the liver were acquired with a 2-T whole-body magnetic, both before and after fructose administration, at 2.5-minute intervals over at least 30 minutes. The fructose load caused a significant, linearly dose-dependent accumulation of phosphomonoesters (r = .72, P less than .01) and a decrease in inorganic phosphate (r = .78, P less than .005) and adenosine triphosphate (r = .73, P less than .01). On the basis of these experiments, dynamic P-31 MR spectroscopy seems promising in the assessment of liver function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2704824     DOI: 10.1148/radiology.171.2.2704824

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

Review 1.  Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer.

Authors:  Pieter C Dagnelie; Susanne Leij-Halfwerk
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  Metabolic control patterns in acute phase and regenerating human liver determined in vivo by 31-phosphorus magnetic resonance spectroscopy.

Authors:  Darren V Mann; Wynnie W M Lam; N Magnus Hjelm; Nina M C So; David K W Yeung; Constantine Metreweli; Wan Y Lau
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

3.  Differential effects of acute versus chronic dietary fructose consumption on metabolic responses in FVB/N mice.

Authors:  Jordan W Strober; Sully Fernandez; Honggang Ye; Matthew J Brady
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-05-17       Impact factor: 3.210

4.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

Authors:  Laura H Tetri; Metin Basaranoglu; Elizabeth M Brunt; Lisa M Yerian; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

5.  Selective protection of human liver tissue in TNF-targeting of cancers of the liver by transient depletion of adenosine triphosphate.

Authors:  Timo Weiland; Kathrin Klein; Martina Zimmermann; Tobias Speicher; Sascha Venturelli; Alexander Berger; Heike Bantel; Alfred Königsrainer; Martin Schenk; Thomas S Weiss; Albrecht Wendel; Matthias Schwab; Michael Bitzer; Ulrich M Lauer
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

6.  Bioactivity-Guided Identification of Botanical Inhibitors of Ketohexokinase.

Authors:  MyPhuong T Le; Miguel A Lanaspa; Christina M Cicerchi; Jatinder Rana; Jeffrey D Scholten; Brandi L Hunter; Christopher J Rivard; R Keith Randolph; Richard J Johnson
Journal:  PLoS One       Date:  2016-06-20       Impact factor: 3.240

Review 7.  In-vivo31P-MRS of skeletal muscle and liver: A way for non-invasive assessment of their metabolism.

Authors:  Ladislav Valkovič; Marek Chmelík; Martin Krššák
Journal:  Anal Biochem       Date:  2017-01-21       Impact factor: 3.365

8.  Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats.

Authors:  Leah R Villegas; Christopher J Rivard; Brandi Hunter; Zhiying You; Carlos Roncal; Melanie S Joy; MyPhuong T Le
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

Review 9.  Health outcomes of a high fructose intake: the importance of physical activity.

Authors:  Luc Tappy; Robin Rosset
Journal:  J Physiol       Date:  2019-06-09       Impact factor: 5.182

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.